AVROBIO, Inc. - AVRO STOCK NEWS

AVROBIO, Inc. announced the grant of non-statutory stock options for 14,500 shares to two new employees under its 2019 Inducement Plan. The options, effective December 1, 2021, have an exercise price of $3.71 per share, matching AVROBIO's closing stock price on that date. These options have a 10-year term and vest over four years, contingent on continued employment. AVROBIO is focused on gene therapy aimed at treating genetic diseases, leveraging its plato® platform for various conditions including Fabry disease and Gaucher disease.

AVROBIO has announced safety data updates from its Phase 1 and Phase 2 clinical trials for Fabry disease and Gaucher disease type 1, indicating no adverse or serious adverse events related to the investigational gene therapy AVR-RD-01. A total of nine Fabry patients have been dosed, with encouraging results in enzyme activity and kidney reduction observed. Additionally, the first Gaucher patient treated has shown no adverse events after 14 months post-treatment. The company plans to present updated efficacy data in early 2022, aiming to enhance patient outcomes in lysosomal disorders.

AVROBIO, Inc (NASDAQ: AVRO), a clinical-stage gene therapy company, announced upcoming participation in investor conferences. Key events include the Barclays Gene Editing & Gene Therapy Summit on November 15, 2021, at 2:30 p.m. ET, and the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 10:00 a.m. ET. Live webcasts of these presentations will be available on the AVROBIO website and replayed post-event. AVROBIO focuses on personalized gene therapies targeting diseases like Fabry and Gaucher disease.

AVROBIO, Inc. (NASDAQ: AVRO) announced its participation in the 14th International Congress of Inborn Errors of Metabolism (ICIEM) from Nov. 21-23, 2021, in Sydney, Australia. The company will present safety data from its clinical trials for Fabry disease and Gaucher disease type 1 through an oral presentation and two poster presentations. One oral presentation will focus on AVR-RD-01, a gene therapy for Fabry disease, while recorded posters will cover the Guard1 clinical trial for Gaucher disease and preclinical outcomes for Mucopolysaccharidosis type II. A symposium on enhancing patient experience during gene therapy will also be sponsored by AVROBIO.

AVROBIO, Inc. (Nasdaq: AVRO) has granted a non-statutory stock option for the purchase of 120,000 shares of common stock to new Chief Medical Officer Essra Ridha, M.D., as part of the 2019 Inducement Plan. The stock option, dated November 1, 2021, has an exercise price of $5.67 per share, aligning with the closing stock price on that date. The option has a 10-year term and vests over four years, contingent on continued employment. AVROBIO aims to advance gene therapy for various genetic diseases including Fabry and Gaucher diseases.

AVROBIO reported a net loss of $32.6 million for Q3 2021, down from $36.8 million in 2020, primarily due to reduced research expenses.

They secured $65 million in non-dilutive financing and received FDA feedback on CMC requirements for the Fabry disease trial, expected to initiate in mid-2022.

With approximately $201.4 million in cash, they have a runway extending into Q4 2023, supporting multiple upcoming clinical trials and data updates.

AVROBIO, a clinical-stage gene therapy company, has received Rare Pediatric Disease Designation from the FDA for its lentiviral gene therapy, AVR-RD-05, aimed at treating Hunter syndrome. This designation is part of a program that promotes the development of treatments for rare pediatric diseases. The first Phase 1/2 clinical trial for AVR-RD-05 is expected to begin in the second half of 2022. Hunter syndrome affects 1 in 100,000 to 170,000 males globally, leading to serious health complications.

AVROBIO, a clinical-stage gene therapy company, appointed Dr. Essra Ridha as Chief Medical Officer. Dr. Ridha brings expertise in clinical development of ex vivo lentiviral gene therapies and has previously guided various AVROBIO programs. The company anticipates launching five new clinical trials in 2022 for diseases such as Fabry and Gaucher. Dr. Ridha's track record and knowledge of AVROBIO's strategy positions her to advance the company's therapies. AVROBIO aims to transform the treatment landscape for lysosomal disorders with its innovative plato® platform.

AVROBIO, a clinical-stage gene therapy company, is set to present at the Jefferies Virtual Gene Therapy/Editing Summit on October 28, 2021, at 10:30 a.m. ET. The event will be accessible via a live webcast on the company's website, with an archived version available later. AVROBIO focuses on personalized gene therapy to combat genetic diseases, utilizing its patented plato® platform. The company is headquartered in Cambridge, Massachusetts, and has clinical programs addressing Fabry disease, Gaucher disease, and cystinosis.